

Supplementary Table 3. Ongoing inflammatory diseases, and circulating levels of CRP and inflammatory cytokines in patients with Torsades de pointes who experienced VF/CA and/or underwent electric shock (TdP-CA/VF/EcS; n=22) compared with those who did not (TdP-noCA/VF/EcS; n=18).

	TdP-VF/CA/EcS	TdP-noVF/CA/EcS	<i>p</i>
Definite inflammatory diseases, n	9/22(41%)	9/18(50%)	0.75
<i>Acute infections</i>	7/22(32%)	5/18(28%)	1.00
Sepsis*	3/22(14%)	3/18(17%)	1.00
Pneumonia*	2/22(9%)	2/18(11%)	1.00
Acute infective endocarditis	1/22(5%)	1/18(6%)	1.00
Urinary tract infection	1/22(5%)	0/18(0%)	1.00
Acute cholecystitis	1/22(5%)	0/18(0%)	1.00
<i>Chronic immune-mediated diseases</i>	2/22(9%)	3/18(17%)	0.65
Rheumatoid arthritis	2/22(9%)	0/18(0%)	0.49
Polymyalgia rheumatica	0/22(0%)	2/18(11%)	0.20
Undifferentiated chronic arthritis	0/22(0%)	1/18(6%)	0.45
<i>Other</i>	0/22(0%)	1/18(6%)	0.45
Acute pancreatitis	0/22(0%)	1/18(6%)	0.45
CRP, mg/dl	2.93(0.1-29.65)	3.24(0.1-18.39)	0.91
Patients with CRP > 0.5 mg/dl, n	17/22(77%)	15/18(83%)	0.71
IL-6, pg/ml	14.3(0.51-182.1)†	8.4(0.68-497.3)††	0.30
TNFalpha, pg/ml	0.61(0.13-81.35)†	0.75(0.6-3.24)††	0.17
IL-1beta, pg/ml	0.15(0.11-5.95)†	0.20(0.1-0.67)††	0.21

CRP: C-reactive protein; TdP: Torsades de pointes; VF: ventricular fibrillation; CA: cardiac arrest; EcS: electric shock; IL-6: interleukin-6; TNFalpha: Tumor necrosis factor alpha; IL-1beta: interleukin-1beta. * In two patients both pneumonia and sepsis were concomitantly detected; † available in 19 out of 22 patients; †† available in 11 out of 18 patients.

Except where indicated otherwise, values are expressed as median (range). Differences were evaluated by the two-tail Mann-Whitney test or by the two-sided Fisher's exact test.